论文部分内容阅读
目的:考察健康人体内达稳态时普卢利沙星对多索茶碱药动学的影响。方法:采用高效液相色谱法测定男性健康受试者给药前、后不同时间点多索茶碱的血药浓度。药-时数据用非线性程序WINNONLIN拟合,求得药动学参数。结果:多索茶碱在健康人体内呈一级吸收一室开放模型;合用前、后测得多索茶碱的主要药动学参数分别为:cmax(10.280±3.234)、(10.958±3.934)mg/L,t1/2a(0.218±0.179)、(0.298±0.182)h,tmax(0.883±0.458)、(1.222±0.475)h,t1/2β(4.770±3.311)、(5.537±3.577)h,AUC0-12hss(90.934±88.380)、(121.774±108.162)mg·h/L。结论:在该给药剂量下,两药合用在药动学上无明显的相互作用,提示两药临床上可以合用,但应注意监测多索茶碱的血药浓度。
Objective: To investigate the effect of prulifloxacin on the pharmacokinetics of doxofylline in healthy subjects. Methods: The plasma concentrations of doxofylline in male healthy subjects before and after administration were determined by high performance liquid chromatography (HPLC). Drug-time data using non-linear program WINNONLIN fitting, obtained pharmacokinetic parameters. Results: Doxofylline showed a first-order model of open-cell absorption in healthy volunteers. The main pharmacokinetic parameters of doxofylline were cmax (10.280 ± 3.234), (10.958 ± 3.934) t 1/2 (0.883 ± 0.458), (1.222 ± 0.475) h, t1 / 2β (4.770 ± 3.311), (5.537 ± 3.577) h, AUC0-12hss (90.934 ± 88.380), (121.774 ± 108.162) mg · h / L. Conclusion: There is no obvious pharmacokinetic interaction between the two drugs at the dosage, which suggests that the two drugs can be used clinically. However, the concentration of doxofylline should be monitored.